<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> is a side effect caused by some therapies for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, which can cause physical, social and psychological harm </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> also prevents attainment of treatment goals and satisfactory glycaemic control </plain></SENT>
<SENT sid="2" pm="."><plain>AREAS COVERED: The risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> associated with commonly prescribed therapies, including <z:chebi fb="0" ids="6801">metformin</z:chebi>, sulphonylureas, dipeptidyl peptidase-4 enzyme (DPP-4) inhibitors, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) <z:chebi fb="4" ids="48705">agonists</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, is reviewed in this paper (insulin-induced <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> is not included) </plain></SENT>
<SENT sid="3" pm="."><plain>Other medications that are frequently co-prescribed in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are also discussed, including anti-hypertensive drugs, antibiotics and fibrates, along with various important patient-related risk factors </plain></SENT>
<SENT sid="4" pm="."><plain>EXPERT OPINION: <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> is a common and potentially dangerous side effect of some medications used for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> should always be considered when selecting and implementing a therapy, with a focus on the individual </plain></SENT>
<SENT sid="6" pm="."><plain>Future research into new therapies should measure the frequency of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> prospectively and accurately </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> has been shown to be a potentially life-threatening metabolic stress; therefore therapies that effectively manage <z:mp ids='MP_0002055'>diabetes</z:mp> without the risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> are likely to be favoured in the future </plain></SENT>
</text></document>